TheraDep Technologies and dsm-firmenich have announced a strategic partnership to develop and commercialize advanced bio-surface and nano-coating technologies for the medical and life science industries.
Key Highlights of the Agreement
-
Strategic Collaboration: The partnership combines TheraDep’s cold plasma deposition platform with dsm-firmenich’s leadership in medical-grade biomaterials.
-
First Product Launch: The initial focus is the launch of BioDep™ medical-grade collagen-coated microplates, which offer superior well-to-well consistency and biological functionality.
-
Core Objectives: The teams aim to improve the reproducibility of in vitro models and medical devices while reducing material waste and variability.
-
Operational Milestone: The agreement was finalized in mid-January 2026 at TheraDep’s facility in Tipperary, Ireland.
